GFRA3 and type 2 diabetes mellitus: Of the 18 RET/GFRα3 inhibitors two molecules with relatively low specificity to the RET kinase, namely PHA-739358 and VEGFR inhibitor V, induced Un3-GFP in the cells with p-values below 0.01, and of the 42 known T2D drugs, only the two potassium-channels blockers, Repaglinide and Tolbutamide, gave marginal results.